SOST and chronic kidney disease: To determine whether sclerostin levels altered Wnt signaling activity in CKD bone, immunofluorescence colocalization analyses were performed with sclerostin and phos-β-catenin, which marks Wnt inhibition, and an unphosphorylated (active) β-catenin antibody, which marks Wnt activity.